CUE BIOPHARMA INC (CUE) Stock News

NASDAQ:CUE - Nasdaq - US22978P1066 - Common Stock - Currency: USD

0.8829 -0.02 (-2.44%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CUE Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Chartmill - Mentions: GTI ACM GAME SRPT ...

News Image

Get insights into the top gainers and losers of Wednesday's after-hours session.

9 days ago - By: Benzinga - Mentions: SSY SRPT PDSB ATHA ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

10 days ago - By: Cue Biopharma, Inc.

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

24 days ago - By: Cue Biopharma, Inc.

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

a month ago - By: Cue Biopharma, Inc.

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

2 months ago - By: Zacks Investment Research - Mentions: FENC

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

2 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

3 months ago - By: Zacks Investment Research - Mentions: MXCT

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

3 months ago - By: Cue Biopharma, Inc.

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

3 months ago - By: Zacks Investment Research - Mentions: IRD

Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline

3 months ago - By: Zacks Investment Research - Mentions: HRMY

Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know

3 months ago - By: Yahoo Finance - Mentions: MU REGN RGEN NVDA ...

Jim Cramer on Micron (MU): “No Catalyst, But You’re Buying Near the Low End”

3 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

3 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Announces Proposed Public Offering

3 months ago - By: Cue Biopharma, Inc.

Cue Biopharma to Host Business Update Call and Webcast

3 months ago - By: Cue Biopharma, Inc.

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

4 months ago - By: Benzinga

What's Going On With Cue Biopharma Shares Tuesday?

4 months ago - By: Zacks Investment Research - Mentions: NRIX

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

4 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

4 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

8 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Cue Biopharma, Inc.

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

8 months ago - By: Cue Biopharma, Inc.

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

8 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

8 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

8 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Announces Strategic Organizational Transition

8 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Announces Strategic Organizational Transition

9 months ago - By: Cue Biopharma, Inc.

Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

9 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

9 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting